Skelaxin vs. Cyclobenzaprine: Which Muscle Relaxant for Personal Injury?

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | November 6, 2025 | 7 min read

Skelaxin (metaxalone) and cyclobenzaprine (Flexeril) are the two most commonly prescribed muscle relaxants in personal injury cases — but they are not interchangeable. The critical difference is sedation: Skelaxin works without significant drowsiness, while cyclobenzaprine causes moderate-to-significant impairment. Here's what that means for PI patients.

Skelaxin vs. Cyclobenzaprine: Which Muscle Relaxant for Personal Injury Patients?

Muscle spasm following personal injury — whether from whiplash, lumbar strain, shoulder injury, or post-surgical recovery — almost always requires pharmacological management. Two medications dominate the prescription landscape: cyclobenzaprine (Flexeril) and Skelaxin (metaxalone). Both are effective. Both are non-controlled. But the decision between them has significant practical consequences for personal injury patients.

[!KEY] Skelaxin (metaxalone) and cyclobenzaprine (Flexeril) both document physician-identified muscle spasm requiring pharmacological intervention, but the choice between them reveals additional clinical information — Skelaxin's non-sedating profile signals a physician prioritizing functional preservation, while extended cyclobenzaprine prescribing at higher doses signals spasm severe enough to accept the sedation trade-off.

The Fundamental Difference: Sedation

Cyclobenzaprine is structurally related to tricyclic antidepressants and produces its muscle-relaxing effect through the central nervous system. That mechanism comes with substantial CNS depression — sedation, cognitive slowing, dry mouth, and impaired coordination. For some patients, that sedation is severe enough to prevent driving, impair work performance, and interfere with cognitive function.

Metaxalone (Skelaxin) operates through a different CNS mechanism that produces muscle relaxation with markedly less sedation. Clinical studies and prescriber experience consistently show that patients taking Skelaxin can function — drive, work, think clearly — in a way that patients on cyclobenzaprine often cannot.

Why Sedation Matters More in PI Cases Than in Other Contexts

In most clinical settings, sedation from a muscle relaxant is a mild inconvenience. In personal injury cases, it is a significant functional limitation:

Driving to Medical Appointments

PI patients attend physical therapy sessions, chiropractic appointments, specialist consultations, IMEs, and pharmacy visits. A sedating muscle relaxant taken three times daily can impair the ability to drive safely. Skelaxin's non-sedating profile means patients can take their muscle relaxant and still drive.

Working During Recovery

Many PI patients continue working part-time or full-time during recovery — either by necessity or to preserve income relevant to their lost wages claim. Sedation impairs job performance for roles requiring concentration, communication, or physical coordination. Skelaxin allows patients to manage muscle spasm without the cognitive toll of cyclobenzaprine.

Physical Therapy Participation

Effective physical therapy requires active patient participation — effort, range of motion, conscious engagement with the exercises. A sedated patient performs physical therapy less effectively. Skelaxin's non-sedating profile supports productive PT sessions.

Legal Participation

PI cases demand cognitive engagement from the patient: attending depositions, reviewing medical records, participating in attorney meetings, maintaining symptom diaries. Moderate-to-severe sedation from cyclobenzaprine undermines the patient's ability to participate meaningfully in their own case.

[!KEY] A Skelaxin prescription signals a prescriber who factored the patient's functional obligations into the treatment decision — this context makes a compelling demand narrative: the patient's injuries required pharmacological muscle spasm management AND were severe enough to affect a working, driving, PT-attending individual whose functional capacity needed to be preserved.

When Cyclobenzaprine Is the Better Clinical Choice

Skelaxin is not always the superior option. Cyclobenzaprine has clinical advantages in specific situations:

Severe spasm with sleep disruption: The sedation from cyclobenzaprine — which many physicians consider a liability for daytime use — becomes a therapeutic advantage at bedtime. Patients with severe spasm that prevents sleep benefit from cyclobenzaprine's sedating properties taken at night. Some physicians prescribe cyclobenzaprine specifically at bedtime for this reason.

Short-term intensive treatment: For acute, severe muscle spasm in the first 72-96 hours after injury, the more potent CNS effect of cyclobenzaprine may provide stronger initial spasm relief. Once the acute phase passes and longer-term management is needed, some physicians transition to Skelaxin.

Patients who are not working or driving: A patient on leave from work who doesn't need to drive may not be significantly disadvantaged by cyclobenzaprine's sedation. For these patients, the clinical calculus changes.

The PI Documentation Angle: What the Prescription Choice Reveals

Both Skelaxin and cyclobenzaprine document physician-identified muscle spasm requiring pharmacological intervention. But they create slightly different records:

A Skelaxin prescription reflects a prescriber who explicitly considered the patient's functional needs — who recognized that this patient needs to work, drive, and remain cognitively engaged — and selected the non-sedating option to preserve those capabilities. This is a more sophisticated clinical decision than defaulting to cyclobenzaprine, and it documents a physician who is actively managing the patient's functional recovery, not just their pain.

A cyclobenzaprine prescription — particularly if taken at higher doses or for an extended period — reflects significant muscle spasm severity. If the physician has determined that the sedating agent is warranted, this implies the spasm is severe enough that the sedation trade-off is acceptable. Extended cyclobenzaprine prescribing documents ongoing, significant muscle spasm.

Extended Use: What Long-Term Prescriptions Mean

Both medications are commonly described as "short-term" in prescribing guidance, but real-world PI prescribing extends well beyond the acute phase when the underlying injury has not resolved. An extended muscle relaxant prescription — whether Skelaxin or cyclobenzaprine — reflects:

• Ongoing physician assessment that muscle spasm has not resolved
• Active, continuing injury management beyond the acute period
• Injury severity sufficient to require sustained pharmacological treatment

Refill records for either medication document ongoing muscle pathology at each refill date, creating a clinical timeline of persistent injury.

[!KEY] Extended cyclobenzaprine prescribing — particularly at 10mg doses or with dose escalations — documents that the treating physician found the sedation burden acceptable given the severity of spasm, a clinical judgment that strengthens the soft tissue injury narrative far more than a modest initial prescription that was not renewed.

Clinical Combinations

Neither medication is typically prescribed in isolation. Common PI regimens pair a muscle relaxant with:

• A topical or oral NSAID (celecoxib, meloxicam, Flector Patch) — addresses underlying inflammation that triggers spasm
• A gabapentinoid (gabapentin, pregabalin, Horizant) — when nerve root involvement is present alongside the musculoskeletal component
• Physical therapy — pharmacological muscle relaxation facilitates range-of-motion work that would otherwise be limited by protective spasm

What Attorneys Should Know

[!TIP] Read the muscle relaxant prescription as a clinical signal: Skelaxin documents a working patient with functional demands; cyclobenzaprine at higher doses or extended duration documents spasm severity that outweighed the sedation risk — both stories strengthen the demand, but in different ways.

A muscle relaxant prescription — regardless of which one — is direct evidence of physician-documented muscle spasm. The distinction between Skelaxin and cyclobenzaprine tells an attorney something additional:

• Skelaxin prescription: Physician recognized significant functional impairment from spasm and selected a non-sedating treatment to preserve the patient's ability to function — a clinically sophisticated choice consistent with treating a working-age patient with ongoing life demands.

• Cyclobenzaprine at higher doses or extended duration: Physician determined the sedating agent was warranted — consistent with significant spasm severity. The sedation side effect itself becomes part of the PI narrative (inability to drive, impaired work performance, need for assistance).

Both tell a story. The attorney's job is to understand which story the specific prescription is telling.

LienScripts covers both Skelaxin and cyclobenzaprine for personal injury patients at $0 upfront cost. Contact LienScripts to discuss pharmacy lien coverage for your clients.

Related Resources

• Skelaxin (Metaxalone): The Non-Sedating Muscle Relaxant for PI Patients
• Why PI Patients Often Need Multiple Medications
• Cyclobenzaprine After a Rear-End Collision
• Cyclobenzaprine for Personal Injury Cases: Attorney's Guide — How cyclobenzaprine prescribing patterns support PI claims